𝗪𝗵𝗲𝗻 𝗶𝘁 𝗰𝗼𝗺𝗲𝘀 𝘁𝗼 𝗚𝗜 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵, 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀. We’re a trusted scientific partner for sponsors advancing therapies for ulcerative colitis, Crohn’s disease, and related indications. This depth of GI-focused scientific leadership allows us to address scientific and operational challenges with precision, accelerate timelines, and generate data sponsors and regulators trust. Discover how our GI expertise can strengthen your program: loom.ly/ZHLio08 #GIIsOurWhy #IBDResearch #ClinicalTrials #Gastroenterology #CROLeadership

Need a CRO that understands the complexities of celiac disease? Alimentiv combines decades of GI expertise with a purpose-built, proven approach to trial design, imaging, and site selection that that recruit patients faster than average, plus a global network spanning 5,000 sites across 60 countries. We’ve helped shape IBD endpoints and advanced GI therapies - now we’re applying that knowledge to accelerate celiac research to bring new therapies to patients, faster. See how we can support your celiac trial. loom.ly/vYXau5c #CeliacDisease #ClinicalTrials #GIResearch #CRO #Alimentiv

𝗛𝗮𝗽𝗽𝘆 #𝗣𝗿𝗶𝗱𝗲 𝗠𝗼𝗻𝘁𝗵 𝗳𝗿𝗼𝗺 𝗔𝗹𝗶𝗺𝗲𝗻𝘁𝗶𝘃! 🌈 Pride reminds us that belonging is at the foundation of our organization. We're proud to bring our whole selves to work, supported by our LGBTQ Employee Resource Group that provides education, advocacy, and connection. Diversity in our workplace and in clinical research is key to the science we do. 🏳️‍🌈⚧️🏳️‍⚧️ Wishing everyone a joyful, safe, and proud month. #PrideMonth #Pride2026 #LGBTQ #InclusiveResearch #LoveIsLove

Celiac disease trials face regulatory and scientific challenges — from a lack of validated endpoints to the difficulty of demonstrating clinical benefit. Alimentiv brings deep GI expertise and country-specific regulatory insight to build the ideal start-up strategy. With decades of trial design and delivery experience, we help sponsors navigate these complexities with confidence. From protocol development and submission through end-of-study reporting, we partner with you to build smarter trials that meet regulatory expectations and move therapeutic progress forward. Explore more: loom.ly/vYXau5c #CeliacDisease #ClinicalTrials #TrialDesign #RegulatoryStrategy #GIResearch #ClinicalDevelopment

In the complex field of clinical research, partnering with a specialized CRO is key. Alimentiv has over 30 years of GI-related experience and offers end-to-end clinical trial services. Our unmatched expertise spans all trial phases, starting from clinical trial management to imaging and precision medicine. We partner with you to deliver innovative solutions for your studies. Learn why we are the trusted partner for leading pharmaceutical & biotech companies: alimentiv.com/resources/end-… #Alimentiv #GIIsOurWhy #ClinicalTrials

💜 𝐖𝐨𝐫𝐥𝐝 𝐄𝐨𝐬𝐢𝐧𝐨𝐩𝐡𝐢𝐥𝐢𝐜 𝐄𝐬𝐨𝐩𝐡𝐚𝐠𝐢𝐭𝐢𝐬 (𝐄𝐨𝐄) 𝐃𝐚𝐲 was established in 2025 to raise awareness and drive action for those affected by this chronic and often underdiagnosed immune condition. At Alimentiv, we support #EoE clinical research and are working to bring new therapies to patients. 🔬 Learn how we’re developing AI-based digital image analysis tools to improve histological assessments in EoE trials: loom.ly/elwW3uE #EoEDay #UniteForEoE #GIIsOurWhy

Scientific leadership is the foundation of better GI trials. That’s why we’ve built a leadership team, scientific advisor group, and global network of key opinion leaders (KOLs) with decades of GI research experience. Our expert team guides clinical development strategies that deliver exceptional outcomes. Learn more about our scientific and therapeutic leadership: loom.ly/gO1V1Xc #GIIsOurWhy #ClinicalResearch #Gastroenterology #ClinicalTrials #IBDResearch

On #ClinicalTrialsDay, we recognize the people who make clinical research possible and the importance of making it accessible to patients everywhere. 🌏 GI disease affects patients on all continents. At Alimentiv, we’re proud to be a global company with an extensive site network – we go where the disease is. Judi Hall, VP, Global Resource Management, explains that it’s the infrastructure, expertise, and collaboration across regions that make GI trials possible. Together, we’re working to expand access, accelerate discovery, and ultimately improve outcomes for patients living with GI disease around the globe. #GIIsOurWhy #CTD2026 #ResearchRising

𝗪𝗵𝘆 𝗚𝗜? Because better data leads to better outcomes — and patients deserve nothing less. For more than 30 years, Alimentiv has led the science of GI clinical trials. From global trial design and patient recruitment to imaging, histopathology, and endpoints you can trust, our purpose‑built GI infrastructure delivers the rigor, consistency, and partnership sponsors need to accelerate development with confidence. We’re proud to have supported over 70% of IBD compounds in development — and we’re just getting started. ✨ 𝗚𝗜 𝗜𝘀 𝗢𝘂𝗿 𝗪𝗵𝘆. Watch our story. #GIIsOurWhy #Alimentiv #GIResearch #ClinicalTrials #DrugDevelopment #IBD

For over 30 years, Alimentiv has led the science of gastroenterology clinical research — 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 >𝟳𝟬% 𝗼𝗳 𝗜𝗕𝗗 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱𝘀 in development, and building a global network of 𝟱,𝟬𝟬𝟬 𝘀𝗶𝘁𝗲𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝟲𝟬 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀. We don’t just run trials, we advance the science behind them. 𝗢𝘂𝗿 𝘂𝗻𝗺𝗮𝘁𝗰𝗵𝗲𝗱 #𝗚𝗜 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘀 𝘁𝗵𝗲 𝗳𝗼𝗰𝘂𝘀 𝗮𝗻𝗱 𝗱𝗮𝘁𝗮 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗱 𝗳𝗼𝗿 𝗲𝘅𝗰𝗲𝗽𝘁𝗶𝗼𝗻𝗮𝗹 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀. See how we advance GI science: loom.ly/nags0iY #GIIsOurWhy #ClinicalTrials #ClinicalResearch #Alimentiv

𝗪𝗵𝗲𝗻 𝗶𝘁 𝗰𝗼𝗺𝗲𝘀 𝘁𝗼 𝗚𝗜 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵, 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀. We’re a trusted scientific partner for sponsors advancing therapies for ulcerative colitis, Crohn’s disease, and related indications. This level of involvement reflects decades of GI-focused scientific leadership that help us navigate complexity, accelerate timelines, and generate that data sponsors and regulators trust. Discover how our GI expertise can strengthen your program: loom.ly/ZHLio08 #GIIsOurWhy #IBDResearch #ClinicalTrials #Gastroenterology #CROLeadership

DDW marked the second conference where we brought GI Is Our Why to life — this time, for the entire GI community. This year was especially meaningful as we unveiled Alimentiv’s refreshed brand and formally introduced our brand story: 𝗚𝗜 𝗜𝘀 𝗢𝘂𝗿 𝗪𝗵𝘆 — a reflection of our deep commitment to advancing GI science across the full spectrum of the gastroenterology field. Thank you to everyone who stopped by our booth, joined our sessions, and shared this milestone with us. Your engagement and collaboration continue to fuel innovation in GI research and reinforce the purpose that drives everything we do. Missed us at DDW? No problem — you can still connect with our GI experts: loom.ly/2GoiBH8 We'll see you next year at #DDW2027 in Washington, D.C.! 🏛️ #GIresearch #DDW2026 #Alimentiv #GIIsOurWhy

A gluten-free diet has long been the only option for people with celiac disease — but it isn’t enough. The need for evidence-based therapies is growing. At Alimentiv, we bring deep GI expertise, validated outcomes measures, centralized imaging and proven trial design to advance new therapeutic options that can change lives. Through our global research network and operational excellence, we’re enabling sponsors to run trials smarter and move the field toward more meaningful outcomes for patients with celiac disease. Explore our celiac focus: loom.ly/vYXau5c #CeliacDisease #ClinicalTrials #GIResearch #BeyondTheDiet #Alimentiv

We’re live at #DDW2026! Stop by booth 4651 to learn how your next trial can benefit from: ⚕️30 years of GI expertise 💊 Trusted for >70% of IBD compounds in development 🌐 5000 sites in 60 countries 🔍 Industry-leading imaging solutions, central reading & access to AI imaging technologies 🔬 State-of-the-art accredited histopathology lab and biomarker discovery #GIIsOurWhy #Alimentiv #ClinicalResearch

𝗗𝗼𝗻'𝘁 𝗳𝗼𝗿𝗴𝗲𝘁 𝘁𝗼 𝗮𝘁𝘁𝗲𝗻𝗱 𝘁𝗵𝗶𝘀 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝗳𝘂𝗹 𝗽𝗼𝘀𝘁𝗲𝗿 𝘀𝗲𝘀𝘀𝗶𝗼𝗻 𝗮𝘁 #𝗗𝗗𝗪𝟮𝟬𝟮𝟲! @vipuljairath will be sharing results from the VECTORS week 14 interim analysis which show early efficacy of vedolizumab in patients with moderately to severely active #CrohnsDisease. 𝐃𝐚𝐭𝐞: May 4, 2026 𝐓𝐢𝐦𝐞: 12:30–1:30 PM CDT 𝐒𝐞𝐬𝐬𝐢𝐨𝐧 𝐓𝐢𝐭𝐥𝐞: Controlled Clinical Trials of IBD Treatment 𝐏𝐨𝐬𝐭𝐞𝐫: Mo1517 See more posters: loom.ly/oOKCp9E #IBD #Alimentiv #GIIsOurWhy

𝗙𝗼𝗿 𝗺𝗮𝗻𝘆 𝗼𝗳 𝘂𝘀 𝗮𝘁 𝗔𝗹𝗶𝗺𝗲𝗻𝘁𝗶𝘃, 𝗼𝘂𝗿 𝘄𝗼𝗿𝗸 𝗶𝘀 𝗻𝗼𝘁 𝗼𝗻𝗹𝘆 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹; 𝗶𝘁’𝘀 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹. It lives in the conversations we carry home, the family members we think about when we read a protocol, and the quiet reason we chose GI. This #CeliacAwarenessMonth, we're launching a new series: 𝗢𝗻𝗲 𝗣𝘂𝗿𝗽𝗼𝘀𝗲, 𝗠𝗮𝗻𝘆 𝗦𝘁𝗼𝗿𝗶𝗲𝘀 — an opportunity to hear from the people behind our work, including our Chief Operations Officer Stephanie Gonzalez — whose daughter lives with celiac disease, and whose experience shapes what she believes this work must deliver. Because behind every biopsy scored, every endpoint validated, every trial that moves forward — there are real patients waiting for better answers. That's what drives us. That's why GI is our focus. #GIIsOurWhy #CeliacDisease #ClinicalTrials #CeliacAwarenessMonth

𝗡𝗼 𝗼𝗻𝗲 𝗵𝗮𝘀 𝗱𝗼𝗻𝗲 𝗺𝗼𝗿𝗲 𝗚𝗜 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝘁𝗵𝗮𝗻 𝗔𝗹𝗶𝗺𝗲𝗻𝘁𝗶𝘃. That experience is more than a number — it reflects decades of scientific leadership, deep therapeutic expertise, and longstanding partnerships across the global GI community. While generalist CROs treat GI as part of a broader portfolio, Alimentiv brings full-spectrum, GI-exclusive expertise to every phase of clinical development. We bring unmatched GI expertise to every endpoint, every site, every phase. That is how we build exceptional outcomes. Sponsors who partner with Alimentiv gain: 🔬 A specialized GI CRO with 30 years of unmatched trial experience, having supported 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟳𝟬% 𝗼𝗳 𝗜𝗕𝗗 𝗰𝗼𝗺𝗽𝗼𝘂𝗻𝗱𝘀 𝗶𝗻 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 👥 Access to a global network of GI KOLs and investigators built over decades 🌏 End-to-end clinical services supported by 𝟱,𝟬𝟬𝟬 𝘀𝗶𝘁𝗲𝘀 𝗶𝗻 𝟲𝟬 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 🎯 The scale, structure, and discipline required to deliver optimal trial outcomes 𝗪𝗵𝗲𝗻 𝗚𝗜 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗶𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗮𝗻𝗱 𝘁𝗵𝗲 𝘀𝘁𝗮𝗸𝗲𝘀 𝗮𝗿𝗲 𝗵𝗶𝗴𝗵, 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗺𝗮𝗸𝗲𝘀 𝘁𝗵𝗲 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲. Connect with Alimentiv at #DDW2026, May 2–5 in Chicago. #GIIsOurWhy #ClinicalResearch #CRO

🥼 Don’t miss our #AI Learning Lab at #DDW2026! Alimentiv and @AcelaBioLab's CAP-accredited histopathology lab is advancing histology analysis through digital AI innovation! We will be showcasing our AI pathology-assisted scoring tools for IEL quantification in celiac disease. Find out how AI augmentation can simplify and standardize histologic scoring in Celiac studies. 📍 @DDWMeeting, Chicago, IL 🗓️ May 3, 11:30 AM-12:00 PM 🗓️ May 4, 12:30-1:00 PM See the full schedule: loom.ly/7IU25tw #CeliacDisease #DigitalPathology #Alimentiv #AcelaBio #DDW2026

VERDICT is the first randomized controlled treat-to-target trial in #UlcerativeColitis. This trial, sponsored and conducted by Alimentiv in collaboration with @TakedaPharma, will provide the only prospective data on optimal treatment targets that will aim to help inform clinical guidelines, regulatory endpoints, and drug development for UC. #ClinicalTrials #Alimentiv #GIIsOurWhy